Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB grew its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 46.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 767 shares of the company’s stock after purchasing an additional 242 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Medpace were worth $255,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. CWM LLC raised its stake in Medpace by 82.6% in the third quarter. CWM LLC now owns 4,241 shares of the company’s stock valued at $1,416,000 after buying an additional 1,918 shares in the last quarter. Exchange Traded Concepts LLC raised its position in shares of Medpace by 47.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 2,981 shares of the company’s stock worth $995,000 after acquiring an additional 963 shares in the last quarter. Swedbank AB purchased a new stake in Medpace during the third quarter worth approximately $7,477,000. Cabot Wealth Management Inc. boosted its holdings in Medpace by 4.5% in the third quarter. Cabot Wealth Management Inc. now owns 15,625 shares of the company’s stock valued at $5,216,000 after purchasing an additional 671 shares in the last quarter. Finally, Vontobel Holding Ltd. increased its stake in Medpace by 137.3% in the third quarter. Vontobel Holding Ltd. now owns 1,424 shares of the company’s stock valued at $475,000 after purchasing an additional 824 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Down 7.5 %

NASDAQ MEDP opened at $327.86 on Wednesday. The firm has a market cap of $10.19 billion, a P/E ratio of 28.71, a P/E/G ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77. The business’s 50-day moving average price is $344.13 and its 200 day moving average price is $349.34.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MEDP. TD Cowen lowered their target price on shares of Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird upped their price objective on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Baird R W downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.